Treatment Visits Sample Clauses

Treatment Visits. Subjects that did not experience significant pain or skin sensitivity in response to the test spots can receive treatments. Each subject will be enrolled and scheduled for two treatments, three weeks apart and return for a follow-up visit three days after the second treatment for evaluation of the treatment area. The following procedures and assessments are required at the treatment visits: Pre-treatment • Confirm continued eligibility regarding inclusion/exclusion criteria • Review any changes in medication, health status or AE from last visit • Assessment of adverse events including a photograph of the affected treatment area if an adverse event occurred • Assessment of concomitant medications • Assign randomized treatment (after 1st treatment visit only) • Apply a topical anesthetic preparation over the treatment areas, if required. (If used, record in the CRF.) Treatment No lotion, gel or coupling medium is to be used in this treatment. The distal part of the applicator should be clean and dry before fitting it with a new 160 pins tip. The skin in the treated area should also be cleaned well (for removal of any lotions, make-up residues, topical anesthetic cream, etc.) and patted dry. Hairs that exist in the areas should be shaved off. • Treatment should be performed while the subject is lying down comfortably; the operator should have easy access to the subject’s treatment area. • Areas of dental crowns, caps, braces, or other metal dental implants may be more sensitive to treatment and the clinician may use dental rolls, gauze or a tongue depressor to isolate the area and make the treatment more comfortable (if the face is treated). • Treatment of subjects in hair-bearing areas may result in some damage to the follicles and subsequent loss of hair. Avoid the xxxxx area (if face is treated) and other hair growing zones if the patient doesn’t wish to have reduction of the hair growth. This treatment may also result in in- grown hairs. • The applicator should be held perpendicular to and in close contact with the skin. • Pressing the trigger will release the RF energy to the skin, creating a stamped imprint in a shape and intensity depending on energies. • The immediate responses, indicative of the desired effect, are erythema and edema in the immediate area of the stamp and possibly also around it. The edema usually appears 1-2 minutes post-treatment and reaches its peak (of up to moderate edema) within 30 minutes. It should be noted that erythema is n...
Sample 1
AutoNDA by SimpleDocs
Treatment Visits. 4 through 16) Subject titration will be completed on Visit 4; subsequently, subjects will return to the site at 4-week intervals for evaluation and to obtain additional study medication. Activities will be as follows: · Obtain weight and waist circumference measurements; · Obtain xxxxx xxxxx; · Assess adverse events (including eye symptoms), if any; · Assess concomitant medications; · Administer *** and ***; *** INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. · Perform OGTT (Visit 4 only); · Collect urine sample for pregnancy test (females of childbearing potential only) and perform pregnancy test; · Perform brief review of lifestyle counseling and answer questions, if any; · Obtain fasting blood samples for blood chemistry testing (Visits 4, 5, 7, 10 and 13 only). · Ensure that the previous dose of trial medications was taken between 20 and 28 hours ago, and obtain a *** blood sample for *** evaluations (if the previous dose of trial medications is outside this window, *** should be postponed for 1 day) (Visits 7 and 10 only); · Obtain samples for biomarkers: C-reactive protein (blood), microalbumin (urine) and creatinine (urine) (Visit 10 only); · Obtain samples for HgbA1c for diabetic subjects only (Visits 7 and 13 only); · Obtain samples for HgbA1c for all subjects (Visit 10 only); · Obtain blood samples for hematology testing (Visit 10 only); · Administer *** for *** and *** (Visits 4, 7 and 10 only); · Administer *** and *** (Visit 10 only); · Perform *** scan *** (Visit 10 only); · Collect study medication from previous visit; assess for treatment compliance and perform drug accountability; · Dispense study medication for the upcoming study interval and provide the proper instructions for use; · Schedule the next study visit in 4 weeks (± 1 week).
Sample 1

Related to Treatment Visits

  • Treatment The Asset Representations Reviewer agrees to hold and treat Confidential Information given to it under this Agreement in confidence and under the terms and conditions of this Section 4.08, and will implement and maintain safeguards to further assure the confidentiality of the Confidential Information. The Confidential Information will not, without the prior consent of the Issuer and the Servicer, be disclosed or used by the Asset Representations Reviewer, or its officers, directors, employees, agents, representatives or affiliates, including legal counsel (collectively, the “Information Recipients”) other than for the purposes of performing Reviews of Review Receivables or performing its obligations under this Agreement. The Asset Representations Reviewer agrees that it will not, and will cause its Affiliates to not (i) purchase or sell securities issued by the Seller or its Affiliates or special purpose entities on the basis of Confidential Information or (ii) use the Confidential Information for the preparation of research reports, newsletters or other publications or similar communications.

  • Treatment of Fees Except as otherwise provided by Law, the fees described in this SECTION 5: (a) do not constitute compensation for the use, detention, or forbearance of money, (b) are in addition to, and not in lieu of, interest and expenses otherwise described in this Agreement, (c) shall be payable in accordance with SECTION 3.1, (d) shall be non-refundable, (e) shall, to the fullest extent permitted by Law, bear interest, if not paid when due, at the Default Rate, and (f) shall be calculated on the basis of actual number of days (including the first day but excluding the last day) elapsed, but computed as if each calendar year consisted of 360 days, unless such computation would result in interest being computed in excess of the Maximum Rate in which event such computation shall be made on the basis of a year of 365 or 366 days, as the case may be.

  • TREATMENT REQUESTED (b) Buyer shall defend, indemnify and hold harmless Myriant from and against all loss, costs, expenses, damages and liability of any kind arising out of any claims of infringement or alleged infringement of any patent or other intellectual property right with respect to (i) the use of Products in any application by Buyer or its affiliates, contract manufacturers or customers, including but not limited to the use of Products alone or in combination with other substances or components; (ii) any modification to the Products by Buyer or its affiliates, contract manufacturers or customers; or (iii) Products furnished, or methods used, by Myriant in accordance with the specifications or instructions furnished by or expressly or implicitly prescribed by Buyer.

  • Treatment of Options (a) At the Effective Time of the Merger, each outstanding option to purchase Company Common Stock (a "Company Stock Option") issued pursuant to the Company's Non-Employee Directors' Stock Option Plan (the "Director Plan") or the Company's Stock Option and Restricted Stock Purchase Plan (the "Option Plan" and, collectively with the Director Plan, the "Company Stock Plans"), whether vested or unvested, shall be deemed to constitute an option to acquire, on the same terms and conditions as were applicable under such Company Stock Option, those shares of Parent Common Stock and CVPs which the holder of such Company Stock Option would have been entitled to receive pursuant to the Merger if such holder had exercised such option in full immediately prior to the Effective Time of the Merger (utilizing the Exchange Ratio as set forth in Section 2.01 of this Agreement), at a price per share equal to (y) the aggregate exercise price for the shares of Company Common Stock purchasable pursuant to such Company Stock Option divided by (z) the number of full shares of Parent Common Stock deemed purchasable pursuant to such Company Stock Option (a "Converted Option"); provided, however, that in the case of any option to which Section 421 of the Code applies by reason of its qualification under Section 422 of the Code ("incentive stock options"), the option price, the number of shares of Parent Common Stock purchasable pursuant to such option and the terms and conditions of exercise of such option shall be determined in order to comply with Section 424(a) of the Code. If the relevant Company Stock Option is not exercised prior to the Maturity Date (as defined in Exhibit A), any CVPs due pursuant thereto shall terminate and become null and void. If the relevant Company Stock Option is exercised, in whole or in part prior to the Maturity Date (as defined in Exhibit A), upon the sale of any shares of Parent Common Stock received upon the exercise of the relevant Company Stock Option, the CVPs due pursuant to such shares sold shall terminate and become null and void.

  • Sale Treatment The Company has determined that the disposition of the Mortgage Loans pursuant to this Agreement will be afforded sale treatment for accounting and tax purposes;

  • Treatment of Shared Contracts (a) Subject to applicable Law and without limiting the generality of the obligations set forth in Section 2.1, unless the Parties otherwise agree or the benefits of any contract, agreement, arrangement, commitment or understanding described in this Section 2.8 are expressly conveyed to the applicable Party pursuant to this Agreement or an Ancillary Agreement, any contract or agreement, a portion of which is a SpinCo Contract, but the remainder of which is a Parent Asset (any such contract or agreement, a “Shared Contract”), shall be assigned in relevant part to the applicable member(s) of the applicable Group, if so assignable, or appropriately amended prior to, on or after the Effective Time, so that each Party or the member of its Group shall, as of the Effective Time, be entitled to the rights and benefits, and shall assume the related portion of any Liabilities, inuring to its respective businesses; provided, however, that (i) in no event shall any member of any Group be required to assign (or amend) any Shared Contract in its entirety or to assign a portion of any Shared Contract which is not assignable (or cannot be amended) by its terms (including any terms imposing consents or conditions on an assignment where such consents or conditions have not been obtained or fulfilled) and (ii) if any Shared Contract cannot be so partially assigned by its terms or otherwise, or cannot be amended or if such assignment or amendment would impair the benefit the parties thereto derive from such Shared Contract, then the Parties shall, and shall cause each of the members of their respective Groups to, take such other reasonable and permissible actions (including by providing prompt notice to the other Party with respect to any relevant claim of Liability or other relevant matters arising in connection with a Shared Contract so as to allow such other Party the ability to exercise any applicable rights under such Shared Contract) to cause a member of the SpinCo Group or the Parent Group, as the case may be, to receive the rights and benefits of that portion of each Shared Contract that relates to the SpinCo Business or the Parent Business, as the case may be (in each case, to the extent so related), as if such Shared Contract had been assigned to a member of the applicable Group (or amended to allow a member of the applicable Group to exercise applicable rights under such Shared Contract) pursuant to this Section 2.8, and to bear the burden of the corresponding Liabilities (including any Liabilities that may arise by reason of such arrangement), as if such Liabilities had been assumed by a member of the applicable Group pursuant to this Section 2.8.

  • Treatment of Certain Information The Borrower acknowledges that from time to time financial advisory, investment banking and other services may be offered or provided to the Borrower or one or more of its Subsidiaries (in connection with this Agreement or otherwise) by any Lender or by one or more subsidiaries or affiliates of such Lender and the Borrower hereby authorizes each Lender to share any information delivered to such Lender by the Borrower and its Subsidiaries pursuant to this Agreement, or in connection with the decision of such Lender to enter into this Agreement, to any such subsidiary or affiliate, it being understood that any such subsidiary or affiliate receiving such information shall be bound by the provisions of paragraph (b) of this Section as if it were a Lender hereunder. Such authorization shall survive the repayment of the Loans, the expiration or termination of the Letters of Credit and the Commitments or the termination of this Agreement or any provision hereof.

Time is Money Join Law Insider Premium to draft better contracts faster.